<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009407</url>
  </required_header>
  <id_info>
    <org_study_id>PO21062</org_study_id>
    <nct_id>NCT05009407</nct_id>
  </id_info>
  <brief_title>CD160 Expression in Corneal Vessels</brief_title>
  <official_title>CD160 Ans Corneal Graft: Expression in Corneal Vessels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic&#xD;
      factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems&#xD;
      to be restricted to some immune cells and to activated endothelial cells. We hypothesized&#xD;
      that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in&#xD;
      corneal graft rejection pathogenesis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After informed consent, patients enrolled for corneal graft surgery at the Robert Debré&#xD;
      University Hospital, Reims, France, will be included.&#xD;
&#xD;
      Routine general and eye examination including cornea photographs will be performed.&#xD;
&#xD;
      During surgery, a quarter of patients' cornea and of donors' corneoscleral rim will be spared&#xD;
      for immunohistochemistry analyzes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Micro-vascular densities</measure>
    <time_frame>1 year</time_frame>
    <description>neovascularization scores quantification of blood (anti-ERG+/anti-D2-40-) and lymphatic (anti-ERG+/anti-D2-40+) vascular structures ; Percentages of those vascular structures marked with anti-CD160</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of those vascular structures marked with anti-CD160 and/or CD105 and/or aSMA</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical blood vascular densities on photographs with help of ImageJ software</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Corneal Graft Rejection</condition>
  <condition>CD160</condition>
  <condition>Angiogenesis</condition>
  <condition>Lymphangiogenesis</condition>
  <arm_group>
    <arm_group_label>HOSTS</arm_group_label>
    <description>patients ongoing corneal transplantation procedure which a full-thickness cornea from the host is replaced by a graft from a donor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DONORS</arm_group_label>
    <description>grafts from donors that would be analyzed</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunohistochemistry and clinical analyses on patients and corneas</intervention_name>
    <description>Immunohistochemistry and clinical analyses on patients and corneas</description>
    <arm_group_label>DONORS</arm_group_label>
    <arm_group_label>HOSTS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        18-year-old or more patients enrolled for penetrating keratoplasty or deep anterior&#xD;
        lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        inclusion criteria :&#xD;
&#xD;
          -  18-year-old or more patients&#xD;
&#xD;
          -  enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries&#xD;
             at the Robert Debré University Hospital, Reims, France&#xD;
&#xD;
          -  considered able to give an informed written consent exclusion criteria :&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandre DENOYER</last_name>
    <phone>03 26 78 78 88</phone>
    <phone_ext>0033</phone_ext>
    <email>adenoyer@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Damien JOLLY</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre DENOYER</last_name>
      <phone>03 26 78 78 88</phone>
      <phone_ext>0033</phone_ext>
      <email>adenoyer@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corneal Graft Rejection</keyword>
  <keyword>CD160</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>lymphangiogenesis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

